Document is current

Article History

Received: 3 March 2022

Accepted: 15 June 2022

First Online: 26 October 2022

Declarations

:

: The study was approved by the ethics´ committee of the Medical University of Vienna. The study was performed in accordance with the Declaration of Helsinki.Patient consent to participate was waived owing to the retrospective nature of the study.

: Consent for publication was obtained from all authors.

: The authors have the following conflicts of interest to declare:Deutschmann Christine: travel grant: MotivaBartsch Rupert: advisory Role: Astra-Zeneca, Daiichi, Eisai, Eli-Lilly, MSD, Novartis, Pfizer, Pierre-Fabre, Puma, Roche, Seagen; lecture Honoraria: Astra-Zeneca, Celgene, Eli-Lilly, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen; research Support: Daiichi, MSD, Novartis, RocheSinger Christian F: research grants, travel grants and speakers honoraria: Novartis, AstraZeneca, Amgen, Roche, Gilead Science, SanofiAventis, Eli LillyGschwantler-Kaulich Daphne: noneMichael Seifert: noneLeser Carmen: noneMarhold Maximilian: honoraria for lectures, advisory board participation and consultation: Roche, Eli Lilly, Novartis, Astra Zeneca, Daiichi Sankyo, Pfizer, MSD, CECOG and Medmedia; travel support: Amgen, Roche, Novartis, Pierre Fabre, Daiichi Sankyo and EisaiBago-Horvath Zsuzsanna: advisory board: Roche, Novartis; educational support: Daichii SankyoPfeiler Georg: grants and honoraria: Pfizer, Roche, Novartis, Eli Lilly, Daichii Sankyo, AstraZeneca, Amgen, MSD, Gilead Science, Pierre Fabre